Australia’s active vaccine safety system
A new large-scale AusVaxSafety study, published in JAMA Network Open, has confirmed the safety of enhanced influenza vaccines used in people 65 years and older in 2018, providing confidence in the ongoing use of influenza vaccines.
Using the AusVaxSafety active vaccine safety surveillance data, this study, led by Alexis Pillsbury from NCIRS, analysed adverse events following immunisation with adjuvanted and high-dose trivalent influenza vaccines as reported by more than 50,000 participants using a short message service (SMS) in 2018. People who received the high-dose trivalent influenza vaccine reported slightly higher rates of adverse events such as fever, injection site pain, injection site swelling or redness than those who received the adjuvanted trivalent influenza vaccine. However, the rates of seeking medical care were low and comparable for both groups.
Influenza is a serious illness that kills thousands of people globally each year. Annual vaccination is the most important public health measure to prevent this disease. Post-marketing vaccine safety surveillance is critical to show how a vaccine is tolerated in real-world use in large populations, and the AusVaxSafety active vaccine safety surveillance system does just that in Australia. It uses data provided by the Australian public to generate safety profiles of the different vaccines administered under the National Immunisation Program.
While the influenza vaccines assessed in this study are no longer used in Australia, this study shows the strength of the AusVaxSafety surveillance system in assuring people in almost real time that the vaccines they are receiving are well-tolerated and safe.
AusVaxSafety is currently monitoring the safety of 2020 influenza vaccines - including the adjuvanted quadrivalent vaccine given to people aged 65 years and older. The 2020 surveillance already includes over 170,000 participants, including over 60,000 people aged 65 years and older, and rates of adverse events, including those needing medical attention, are reassuringly low.
Access the 2020 influenza vaccine safety data here.
AusVaxSafety receives fundingfrom the Australian Government
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2020 AusVaxSafety. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS
Stay updated with the latest from ausvax